Please Wait
Applying Filters...
menu
    • menu
    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Menu

    Amifampridine Phosphate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,526Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Confirms Paragraph IV Patent Litigation for Amifampridine Phosphate Tablets
    FDA Confirms Paragraph IV Patent Litigation for Amifampridine Phosphate Tablets

    13 Feb 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-amifampridine-phosphate-tablets-60789.pdf

    FDA
    13 Feb 2023
    Share Share
    Serb SA's Amifampridine Serb (amifampridine) Receives Approval in Europe
    Serb SA's Amifampridine Serb (amifampridine) Receives Approval in Europe

    25 May 2022

    // EMA

    https://www.ema.europa.eu/en/documents/overview/amifampridine-serb-epar-medicine-overview_en.pdf

    EMA
    25 May 2022
    Share Share
    KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE in Canada
    KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE in Canada

    28 Oct 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/kye-pharmaceuticals-announces-commercial-availability-of-firdapse-and-174-in-canada/#:~:text=(%22KYE%22)%2C%20a,Canada%2C%20is%20now%20widely%20available

    BIOSPACE
    28 Oct 2020
    Share Share
    Catalyst Pharma and KYE Pharmaceuticals Announce Agreement to Make Firdapse®
    Catalyst Pharma and KYE Pharmaceuticals Announce Agreement to Make Firdapse®

    18 Aug 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/08/18/2079886/0/en/Catalyst-Pharmaceuticals-and-KYE-Pharmaceuticals-Announce-Agreement-to-Make-Firdapse-amifampridine-phosphate-Available-to-LEMS-Patients-in-Canada.html

    GLOBENEWSWIRE
    18 Aug 2020
    Share Share
    Catalyst Pharmaceuticals’ Firdapse® Receives Marketing Approval in Canada
    Catalyst Pharmaceuticals’ Firdapse® Receives Marketing Approval in Canada

    06 Aug 2020

    // GLOBENEWSWIRE

    http://www.globenewswire.com/news-release/2020/08/06/2074199/0/en/Catalyst-Pharmaceuticals-Firdapse-amifampridine-phosphate-Receives-Marketing-Approval-in-Canada-for-Patients-with-LEMS.html

    GLOBENEWSWIRE
    06 Aug 2020
    Share Share
    Catalyst's lead candidate Firdapse falls short Congenital Myasthenic Syndromes
    Catalyst's lead candidate Firdapse falls short Congenital Myasthenic Syndromes

    31 Oct 2019

    // PHARMAFILE

    http://www.pharmafile.com/news/532428/catalysts-lead-candidate-firdapse-falls-short-congenital-myasthenic-syndromes

    PHARMAFILE
    31 Oct 2019
    Share Share